The Week Force: Why stem cells don’t sell

by Jonny Bowers

I’ll be upfront; this week’s entry is liable to consist merely of me ranting. The story I chose is one on a theme that riles me: it was announced this week that Geron, a large US-based biotech company, are closing down their human trial which uses stem cells to help repair the spinal cords of paralysis victims. Their reasoning: lack of funds, and the difficult financial conditions. Possibly the most upsetting thing about this story for me is that it was shut down so soon after it started, as the go ahead for the trial had only been given in 2009.

Geron and their research into stem cell treatments shot to fame in the late Nineties, with the highly publicised case of Christopher Reeve, an actor known best for his role as superman. In 1995 Reeve had a riding accident which damaged his spine and left him paraplegic. Unwilling to give up and accept he would never walk again, Reeve invested much of his time and effort into championing research into stem cell treatments. His legacy since his death in 2004 has included a foundation set up in his name that continues to support and promote these treatments.

At the time of Reeve’s death, the future of stem cell research looked bleak. Especially in the US, the pace was sickeningly slow, not due to the vastly complicated science so much as the red tape in the Bush administration and the protests against the potentially life changing treatments. Since then, things have improved; stem cell research is moving on, its image in the public eye has been greatly enhanced, and many governments now fund or support research programmes. The trials that Geron were carrying out were the first of their kind, a step into the great unknown of science that had to be given time and space to develop. Unfortunately, of the 4 test subjects, none had shown any visible improvement, and hence the study is being dropped in favour of more lucrative endeavours into cancer drugs.

Now, please don’t misunderstand me, I don’t doubt that the development of said drugs will greatly improve and revolutionise the treatment of their respective diseases, not at all. What riles me is the decision to scrap a study of great scientific promise just 2 years after its conception. No, the human subjects hadn’t shown any visible improvement, but looking at the results of the study more closely we can see great promise. The treatment was being honed on rats (as is common and unfortunately necessary in most medical trials) and in the tests there were hopeful results. Whilst no paralysed rats regained the ability to walk, some of those treated had been able to respond and move their hind legs. This is incredible progress.

What really upsets me about the whole story is this: somewhere at Geron, the decision has been made to scrap this trial after only two years of running, simply because there are no tangible products in the direct pipeline. You can’t blame Geron – they’re a company that exists to make a profit, that’s their prerogative and their focus. However, this comes at a time when science funding is being slashed massively by governments globally, and these same governments are justifying this to their people with a simple get out clause: “the private sector will pick up the slack”. Well this is my reply – look at this case and consider it. This is a great piece of scientific research with genuine possibilities in terms of treatments and progress and eventually profit; if the private sector chooses to shun studies like this then what hope do we have?

So, I’ll finish with what seems to me to be a fantastically obvious suggestion: Governments. Don’t slash scientific funding. If we lose out now then we’ll pay in more than money in the future.

This story, as well as many others, will be discussed and dissected on “The Week Force”, which airs on Purple Radio every Saturday from 3-4pm. Any comments are welcome, and you might even get a mention on the show!